ライフサイエンスコーパス: lost to follow-up

1 ccessful in 14 of 15 patients (1 patient was lost to follow-up).

2 strated 12 seroconversions (1 individual was lost to follow-up).

3 substantial improvement in 3 patients (1 was lost to follow-up).

4 ed 71 hard events over 24 +/- 7 months (0.2% lost to follow-up).

5 84 through 1997 were reviewed (1 patient was lost to follow-up).

6 group, and followed for median 2.3 years (5% lost to follow-up).

7 ant), of which 37 were excluded (awaiting or lost to follow-up).

8 y with mRS scores of 0 or 1 (2 patients were lost to follow-up).

9 se of ineligibility and 14 participants were lost to follow-up).

10 tive at their 6-week follow-up visit (4 were lost to follow-up).

11 103 families dropped out or were lost to follow up.

12 en of the children who survived infancy were lost to follow up.

13 13 died in the neonatal period and four were lost to follow up.

14 One intervention cluster was lost to follow up.

15 roup after parasite clearance and three were lost to follow-up.

16 One patient in each group was lost to follow-up.

17 eat, excluding participants who died or were lost to follow-up.

18 Four patients (5%) were lost to follow-up.

19 o-treat (n = 347), including 73 participants lost to follow-up.

20 Eight patients were lost to follow-up.

21 patients of group B became negative; one was lost to follow-up.

22 days in the matched cohort; no patients were lost to follow-up.

23 Three cases were lost to follow-up.

24 nd of study, had the LVAD explanted, or were lost to follow-up.

25 ss, death, biopsy-proven acute rejection, or lost to follow-up.

26 Three patients were lost to follow-up.

27 stomosis, 2 died of other causes, and 3 were lost to follow-up.

28 No patient was lost to follow-up.

29 s do not account for outcomes among patients lost to follow-up.

30 Two patients were lost to follow-up.

31 ere were 97 graft failures, 75 deaths, and 1 lost to follow-up.

32 transferred out of the program, and 34% were lost to follow-up.

33 an follow-up = 118 weeks; 29 (6%) women were lost to follow-up.

34 -up lasted 3 years, and <1% of patients were lost to follow-up.

35 p and 17 women in the cefpodoxime group were lost to follow-up.

36 ollow-up and to describe individuals who are lost to follow-up.

37 s in 2005 were used for 61 patients who were lost to follow-up.

38 ollow-up was 1012 days, and no patients were lost to follow-up.

39 wo patients from each group were immediately lost to follow-up.

40 Three patients were lost to follow-up.

41 ween ages 3 months and 7 years, and 152 were lost to follow-up.

42 nfants died in the first 3 months and 8 were lost to follow-up.

43 rvival information for participants who were lost to follow-up.

44 home and 9 (2%) receiving facility care were lost to follow-up.

45 unodeficiency syndrome, 49 died, and 90 were lost to follow-up.

46 ree and were censored on January 1, 1996, or lost to follow-up.

47 sent and thus was excluded from analyses and lost to follow-up.

48 years (0-11.3 years) with 21 patients (17%) lost to follow-up.

49 ned protocol, and two of these patients were lost to follow-up.

50 hieved a sustained viral response, and 1 was lost to follow-up.

51 ollow-up time was 325 days, 2 patients being lost to follow-up.

52 in the pitrakinra group dropped out or were lost to follow-up.

53 o were not given prophylaxis, and three were lost to follow-up.

54 n care, 21 (9%) were dead, and 24 (10%) were lost to follow-up.

55 One patient was lost to follow-up.

56 gery, and there were no dropouts or patients lost to follow-up.

57 to continue the trial and 3219 children were lost to follow-up.

58 26 (0.3%) individuals dropped out or were lost to follow-up.

59 to 1 year of treatment with trastuzumab were lost to follow-up.

60 70 months); one patient with one lesion was lost to follow-up.

61 ndergone airway stent retrieval, and one was lost to follow-up.

62 nated because of adverse events, and one was lost to follow-up.

63 f referred potential live kidney donors were lost to follow-up.

64 sons tested were similar to those of persons lost to follow-up.

65 None was lost to follow-up.

66 66 patients, with eight (26%) of 31 patients lost to follow-up.

67 .3%) of 166 patients, with 36 (26.7%) of 135 lost to follow-up.

68 er donation, 5 were asymptomatic, and 2 were lost to follow-up.

69 here were 353 live births and 25 pregnancies lost to follow-up.

70 Four patients were lost to follow-up.

71 ion before an end-point was reached, or were lost to follow-up.

72 No other patients were lost to follow-up.

73 s, two did not receive treatment and 46 were lost to follow-up.

74 count participants who had withdrawn or were lost to follow-up.

75 Seven lesions were in patients lost to follow-up.

76 , 114 (21.3%) had emigrated, and 5 (1%) were lost to follow-up.

77 Forty (1.7%) were lost to follow-up.

78 Ninety-seven patients were lost to follow-up.

79 Three survivors were lost to follow-up.

80 y, 48 underwent repeat biopsy and three were lost to follow-up.

81 Five patients were lost to follow-up.

82 women in PM+ (25%) and 49 women in EUC (23%) lost to follow-up.

83 Three were lost to follow-up.

84 not be determined in three patients who were lost to follow-up.

85 spond to conservative treatment, and 35 were lost to follow-up.

86 Four patients were lost to follow-up.

87 Two relatives in each group were lost to follow-up.

88 4 had normal follow-up or delivery; six were lost to follow-up.

89 E); 26 withdrew before surgery and four were lost to follow-up.

90 apy, have discontinued therapy, or have been lost to follow-up.

91 before being lost to follow-up, and one was lost to follow-up.

92 ) spontaneously aborted, and nine (53%) were lost to follow-up.

93 ied linkage to care status and 78 (10%) were lost to follow-up.

94 No patients have been lost to follow-up.

95 7 were alive but unavailable, and 1 had been lost to follow-up.

96 s were followed through to 24 months, with 1 lost to follow-up.

97 f any cause, and 3804 who emigrated and were lost to follow-up.

98 e-dose i.v.: n = 333); 139 participants were lost to follow-up.

99 uncture group and 13% in the sham group were lost to follow-up.

100 2 children were lost to follow-up.

101 Ten patients were lost to follow-up.

102 ve the assigned treatment and the 5 who were lost to follow-up.

103 at less than 24 months, and six (4.7%) were lost to follow-up.

104 ot procedure related; p = 0.055), and 9 were lost to follow-up.

105 93.5%) achieved SVR12, 6 relapsed, and 1 was lost to follow-up.

106 test, 33 died before follow-up and 167 were lost to follow-up.

107 ared gonorrhoea before treatment and 10 were lost to follow-up.

108 Four participants were lost to follow-up.

109 No patient was lost to follow-up.

110 infants died or were stillborn and two were lost to follow-up.

111 Two patients in each group were lost to follow-up.

112 entire population, including those who were lost to follow-up.

113 , three withdrew from the study, and one was lost to follow-up.

114 One patient was lost to follow-up.

115 analysis included only children who were not lost to follow-up.

116 w-up time exceeded 6 years, with no patients lost to follow-up.

117 Two patients were lost to follow-up.

118 One participant was lost to follow-up.

119 treatments whereby 1 participant per arm was lost to follow-up.

120 me, 18 children (PQ arm: 7, PL arm: 11) were lost to follow-up.

121 onths, all patients were alive and none were lost to follow-up.

122 and 3,898 (11.3%) in the control group were lost to follow-up.

123 re unrelated to hepatitis C (1 patient), and lost to follow-up (1 patient).

124 ieved cure or probable cure, 29 (13.7%) were lost to follow-up, 10 (4.7%) experienced treatment failu

125 Including deaths and those lost to follow up, 15 (13.2%) were non-practicing; 5 vol

126 % (426 of 2454 deaths, including 52 patients lost to follow-up): 179 of 397 (45.1%) deaths were ascri

127 d follow-up, 11% withdrew early, and 4% were lost to follow-up; 19% discontinued their regimen premat

128 Of the 19 patients not lost to follow-up, 2 regained weight, with recurrence of

129 hs, eight participants had withdrawn or were lost to follow-up, 280 (94%) individuals provided primar

130 Seven eyes were lost to follow-up, 4 eyes abandoned wearing the scleral

131 Three patients were lost to follow-up, 4 patients died from complications of

132 stational age of 27+/-6 weeks, there were 11 lost to follow-up (5%), 15 terminations (6%), and 41 dem

133 ith uninterpretable studies (1%) and 35 (6%) lost to follow-up, 508 women (mean [+/-SD] age 55 +/- 11

134 Only 153 (5%) children were lost to follow-up (76 in the co-trimoxazole group and 77

135 We identified a random sample of patients lost to follow-up (9 months without a visit).

136 ted follow-up, 7% stopped early, and 9% were lost to follow-up; 9% discontinued their regimen early.

137 ecember 2010, nine (5%) of 211 patients were lost to follow-up; 94 (45%) of 211 are alive and 88 (94%

138 5780 patients (17%) were lost to follow-up, 991 (17%) were selected for tracing b

139 the intervention group and 20 controls were lost to follow-up; a further ten women assigned to the i

140 No eyes were lost to follow-up after 12 months.

141 clinic in Uganda, where 29% of patients were lost to follow-up after 2 years (January 1, 2004-Septemb

142 patients had viral relapse; one patient was lost to follow-up after achieving sustained virological

143 single patient who did not achieve SVR12 was lost to follow-up after achieving SVR4.

144 ies, six improved spontaneously, and one was lost to follow-up after exposure stopped.

145 ir, and GS-9451 for 6 weeks (one patient was lost to follow-up after reaching sustained viral respons

146 euronal ceroid lipofuscinosis; one child was lost to follow-up after the first visit and nine patient

147 age 4A, 4B, and 5) at presentation and those lost to follow-up after treatments were excluded.

148 After randomization, 4 patients were lost to follow-up, all after month 18, and 1 withdrew du

149 nsferred back to the referring physician and lost to follow-up, all patients with reported pulmonary

150 None was lost to follow-up, although 20 discontinued intervention

151 f 5.9 years, 17.8% developed PAD, 13.0% were lost to follow-up and 11.1% died.

152 up) were contacted, whereas 18 patients were lost to follow-up and 20 patients had died.

153 A total of 3.1% of patients were lost to follow-up and 3.2% of patients withdrew consent.

154 Among 18 081 patients, 3150 (18%) were lost to follow-up and 579 (18%) were traced.

155 were excluded, and 70 without follow-up--63 lost to follow-up and 7 new to the study--were excluded

156 Only seven patients were lost to follow-up and are presumed to have become homele

157 One patient was lost to follow-up and died after 240 days of support.

158 detained patients had 4 times the proportion lost to follow-up and half the proportion completing the

159 We traced a random sample of patients lost to follow-up and incorporated updated information i

160 822 patients were lost to follow-up and not included in the main analysis;

161 Eight patients were lost to follow-up and six had RD after therapy.

162 ue with follow-up visits, or 2) patients are lost to follow-up and their outcome data are missing.

163 40 patients were lost to follow-up and were censored.

164 Two patients relapsed, 2 were lost to follow-up, and 1 withdrew consent.

165 Of 1,609 children, 4 died, 61 were lost to follow-up, and 119 were transferred out due to s

166 At 6 months, 51 patients were lost to follow-up, and 17 were alive with unknown status

167 ere in the reference group, 8% (n = 46) were lost to follow-up, and 2% (n = 12) died without POD less

168 echnetium-99m sestamibi MPS, 254 (4.1%) were lost to follow-up, and 586 with early revascularization

169 of the study, fewer than 1 percent had been lost to follow-up, and compliance was 78 percent in the

170 chronic rejection, liver failure after being lost to follow-up, and complications of cystic fibrosis.

171 g did not receive the study drug and one was lost to follow-up, and one patient assigned to receive p

172 died a mean of 5 months afterward, two were lost to follow-up, and one was alive 7 months later.

173 ne had death of one twin embryo before being lost to follow-up, and one was lost to follow-up.

174 4 weeks after the end of treatment but were lost to follow-up, and one was reinfected.

175 None were lost to follow-up, and serial echocardiography was obtai

176 number of individuals with PLC, participants lost to follow-up, and the large proportion of participa

177 Two women were lost to follow-up, and there were 15 protocol violations

178 of events in each group, number of patients lost to follow-up, and trial characteristics, were extra

179 icipants in the standard care group had been lost to follow-up, and were censored at their last visit

180 In 23 (62%) of 37 patients not lost to follow-up, ascites was controlled successfully a

181 reatment, 8 underwent splenectomy, and 1 was lost to follow-up at 10 months.

182 xperienced virologic relapse, and 1 (2%) was lost to follow-up at 4 weeks after treatment.

183 s and 19% of control group participants were lost to follow-up at 6 months.

184 blation with biventricular pacing; none were lost to follow-up at 6 months.

185 Three patients were lost to follow-up at 63, 39, and 4 months after treatmen

186 Three patients who were disease-free were lost to follow-up at 7 months, 21 months, and 10.5 years

187 Six patients were lost to follow-up at a mean of 20 months after surgery.

188 ve survived to 36-months postinjury but were lost to follow-up at all time points.

189 On average, studies have 30% of patients lost to follow-up at the stated end-point.

190 On average, 31% were lost to follow-up at the study's end.

191 ued (one withdrew consent at week 8, one was lost to follow-up at week 12).

192 cs of respondents, nonrespondents, and women lost to follow-up because of an unknown address.

193 60 patients died and three patients were lost to follow up before the 6-month analysis.

194 Eight mothers were lost to follow-up before delivery.

195 ncope recurrences, and only 14 patients were lost to follow-up before syncope recurrence.

196 were excluded from the analysis if they were lost to follow-up before the end of first trimester.

197 the imiquimod group either withdrew or were lost to follow-up before the first 6-week safety assessm

198 was not known for 143 (1%) patients who were lost to follow-up (benazepril plus amlodipine, n=70; ben

199 He was then lost to follow-up but later was seen with worsening atax

200 Two patients were lost to follow-up, but were included in analyses.

201 5 patients (four for mortality outcome) were lost to follow-up by June 30, 2015.

202 15,270 patients were deemed lost to follow-up by the end of the study.

203 ollowed up elsewhere or moved (n = 35), were lost to follow-up by their physicians (n = 17), or were

204 Six women were lost to follow-up; data from 655 were analyzed (325 in t

205 ) analysis assumed all participants who were lost to follow-up, died, or stopped ART as having virolo

206 e candidates were excluded because they were lost to follow-up during the fitting process.

207 ons were required, nor were any participants lost to follow-up during the investigation.

208 ustained virologic response at 12 weeks were lost to follow-up either during or after treatment.

209 incorporation of outcomes from the patients lost to follow-up, estimated 3 year mortality increased

210 No patient was lost to follow-up evaluation.

211 n who consented for ancillary KEEPS-Cog were lost to follow-up for cognitive assessment (3MS and cogn

212 Five patients (14%) have been lost to follow-up for more than 2 years but at last avai

213 low-up by their physicians (n = 17), or were lost to follow-up for other reasons (n = 5).

214 None of the patients were lost to follow-up for the main outcome.

215 participants who withdrew and three who were lost to follow-up from the AQ-13 group, did not meet the

216 No patient was lost to follow-up (>/= 12 months in all patients).

217 re infected with HIV and on ART and who were lost to follow-up (>90 days late for last scheduled visi

218 analysis assuming that 60% of the population lost to follow-up had died gave 3000 additional deaths,

219 ed as normal, and none of five patients (one lost to follow-up) had biliary atresia or other surgical

220 ence in 21 (28%), operation in 28 (38%), and lost to follow-up in 1 (1%).

221 Because many of these ACHD patients are lost to follow-up in adulthood, pregnancy represents a t

222 ient each in arms B and C (two patients were lost to follow-up in arm C).

223 in the ART stage; 2247 (3.9%) patients were lost to follow-up in pre-ART stage and 2847 (2.2%) lost

224 No patients dropped out or were lost to follow-up in study 1; in study 2, two patients i

225 Patients lost to follow-up in the first year were excluded.

226 99%) of 518 patients (five participants were lost to follow-up in the intervention group and one in t

227 that death is a cause of being classified as lost to follow-up in this setting, revealed "collider" b

228 A total of 1685 patients (13.36%) were lost to follow-up, leaving 11,821 patients (86.64%) for

229 Three participants in each group were lost to follow-up, leaving 247 analysed per group.

230 Of 63 randomized patients, 3 were lost to follow-up, leaving 39 TF and 21 COP for analyses

231 andomized, 13 were never revised and 34 were lost to follow-up, leaving a final comparison between 89

232 four South African cohorts in which patients lost to follow-up (LTF) could be linked to the national

233 ciency virus (HIV)-infected patients who are lost to follow-up (LTFU) on reengagement has not been ri

234 ng death rates among adult patients who were lost to follow-up (LTFU).

235 World Health Organization (WHO) targets for lost-to-follow-up (LTFU), ART prescribing practices, and

236 Ten of 60 patients were lost to follow-up(LTFU) or refused further treatment (RF

237 Following LVRS, with none lost to follow-up, mortality due to respiratory failure

238 hs of the stress test (n = 16, 3%) and those lost to follow-up (n = 21, 4%), the remaining 463 patien

239 mes heart or heterotaxy syndrome or who were lost to follow-up (n = 24) were excluded.

240 ine patients were excluded because they were lost to follow-up (n = 41) or had clinical follow-up of

241 analysis for non-virological reasons (death, lost-to-follow-up [n=2], non-compliance, patient withdra

242 irin arm and the 16-week plus ribavirin arm (lost to follow-up, n = 1), respectively.

243 y complete pseudoaneurysm thrombosis and was lost to follow-up on discharge.

244 Nine children were lost to follow-up (one in chloramphenicol group; eight i

245 43 patients were lost to follow-up or discontinued the assigned intervent

246 g women, 40 women (22 iron, 18 placebo) were lost to follow-up or excluded at birth; 12 mothers were

247 Nine women were lost to follow-up or had elective termination.

248 omen, were assessed; 32 treatment cases were lost to follow-up or lost owing to death.

249 patients with positive antibody results were lost to follow-up or refused biopsy (only one EMA-positi

250 h CD4 less than 100 cells per muL on ART but lost to follow-up or with virological failure.

251 troviral therapy (31 patients, 1 of whom was lost to follow-up) or antiretroviral therapy alone (29 p

252 ients (18%) with unfavorable outcomes (died, lost to follow-up, or stopped treatment).

253 4 count 550 cells/microL), 1294 (20%) became lost to follow-up over 2.5 years.

254 nd 112 (7%) participants, respectively, were lost to follow-up over median 4.9 years' follow-up.

255 on-to-treat basis with participants who were lost to follow-up (patch alone [n = 13] and combination

256 low-up or excluded at birth; 12 mothers were lost to follow-up postpartum (5 iron, 7 placebo).

257 ectively terminated their pregnancy, 12 were lost to follow-up prior to completion of pregnancy, and

258 s' in a complex health care system: becoming lost to follow-up, receiving inadequate care, or requiri

259 ients resumed continuous IM and all but one (lost to follow-up) regained CCgR and MMR.

260 year, 26 (9%) and 50 (18%) participants were lost to follow-up, respectively.

261 Seven women were lost to follow-up, six withdrew consent, one died, and t

262 Five participants were lost to follow-up, so the primary analysis included 81 p

263 Given the proportion of patients lost to follow up, these findings merit further confirma

264 not return their case report forms and were lost to follow-up; these patients were not included in o

265 y-evaluable population, which excluded women lost to follow-up, those aged over 35 years, women with

266 Only seven women were lost to follow-up through December 2005.

267 3%) prematurely discontinued therapy or were lost to follow-up; thus, sustained response rates with p

268 suming varying proportions of the population lost to follow-up to be dead.

269 cohort, through September 1, 2013 (with 1.1% lost to follow-up), to address whether there is a relati

270 The analysis in which lost to follow-up was assigned to failure yielded a risk

271 -up but including those who withdrew or were lost to follow-up, we assessed 80 of 99 patients (81%) a

272 Patients lost to follow-up were censored on the date of their las

273 vents such as graft loss, patient death, and lost to follow-up were censored.

274 e intent-to-treat approach in which patients lost to follow-up were considered as having clinical cur

275 e intent-to-treat approach in which patients lost to follow-up were considered as having not responde

276 After patients lost to follow-up were excluded, the study population wa

277 Equivocal cases and any cases lost to follow-up were excluded.

278 Subjects lost to follow-up were more likely than those retained t

279 ts were obtained when participants that were lost to follow-up were treated as smokers (268 [9%] of 2

280 ho on follow-up (mean, 1.6+/-0.5 years; 3.6% lost to follow-up) were found to have 70 hard events (2.

281 underwent fertility-sparing surgery, one was lost to follow-up when she was pregnant, and one was sti

282 ithdrew consent during the trial, and 4 were lost to follow up, which left 798 participants in the as

283 More African American donor referrals are lost to follow-up while rates of other reasons were simi

284 rt of 50 patients (6 with incomplete data or lost to follow-up) with acute second-degree burns from a

285 imultaneous nonkidney transplants, death, or lost to follow-up within 90 days were excluded, unless a

286 1,388 baseline participants died and 81 were lost to follow-up, yielding 11,833 person-years of obser

287 Accounting for outcomes among those lost to follow-up yields a more informative assessment o